relationship not yet fully understood. Investigation has been limited thus far by a paucity of data on the overlap of these disorders in pediatric patients.
A topic dermatitis (AD) and allergic contact dermatitis (ACD) are 2 of the most commonly recognized pediatric inflammatory skin disorders, but they have a dynamic relationship that is not fully understood. For patients with AD, concomitant undiagnosed ACD may result in treatmentresistant disease 1 leading to increased patient morbidity, economic burden, and lost work and/or school days. 2 Diagnosis of ACD in patients with AD is associated with improvements in cutaneous symptoms as patients become able to avoid detected allergens that could potentially aggravate their underlying AD. 1 Because AD is most commonly a disease of childhood, and trends show that the incidence of AD and atopy are increasing, 3 understanding the interplay between AD and ACD is especially important in the pediatric population. A limited number of studies have investigated the overlap of AD and ACD in children. Multiple studies found increased sensitization rates to various allergens among children with AD, including potassium dichromate, Compositae mix, disperse blue, balsam of Peru, fragrance mix, and lanolin. 1, 4, 5 However, these study were limited by small sample size, narrow age range, and restricted geographical distribution of test patients. One of the largest evaluations of children with ACD was done by Zug et al 6 from the North American Contact Dermatitis Group (NACDG), which evaluated 7 years of patch-test results from children 0 to 18 years of age, with a total of 883 children within the sample. Zug et al 6 reported that children had increased prevalence of atopic disorders compared with adults. However, AD was not a primary focus of this study, and no demographic analysis was performed for patients with concomitant AD and ACD. 6 The Pediatric Contact Dermatitis Registry (PCDR) was developed to gather data on pediatric ACD, its associated demographics, and related conditions. Established in 2014, the PCDR is a collaborative, multidisciplinary, nationwide registry of 1142 patch-tested children with data provided by 252 health care providers (physicians, nurse practitioners, physician assistants) from all 50 states. 7 Herein, using data from the PCDR, we focus specifically on the interplay between AD and ACD, with the goal of elucidating the sensitizations among patients with AD.
Methods
This retrospective case review was approved by the Loma Linda University internal review board. In 2015, data for this study were gathered from the PCDR, a multidisciplinary, electronic data registry of patch-test results from children 0 to 18 years of age in the United States. Methodology for the PCDR development and a full description of providers contributing to the registry may be found elsewhere. 7 The data collected for each case included a deidentified database collecting demographic information (age, sex, race); medical history, including diagnosis of AD; clinical information on active dermatitis (anatomic location and duration); and logistical information regarding the patch-testing technique (type of patch test used, date of patch test, time intervals for patch-test evaluation, and allergen results). Allergen results were reported as either positive, relevant positive, or irritant; grading of results was not included in the survey. Positive patch-test (PPT) reactions included any reaction from macular erythema to a 3+ reaction as defined by the International Contact Dermatitis Research Group. Relevance of a PPT was interpreted and defined by the diagnosing providers and submitted within the survey, not verified by the primary investigative team. The medical history and diagnostic findings were not verified by independent review because medical records were not accessible to the primary investigative team. Specifically, the diagnosis of AD was made by the case-entering provider on a case-by-case basis.
Within this analysis, the percentage of PPT (PPT%) was defined for each allergen as the sum of patients who had a positive reaction divided by the total number of patients patchtested for that specific allergen. The percentage of clinically relevant positive patch tests (RPPT%) for each allergen was calculated using the same approach. The percentage of having at least 1 positive or relevant reaction was calculated by dividing the sum of patients with at least 1 positive or relevant reaction, respectively, by the total patients within the study.
Cases were arranged into 2 statistically independent groups (patients with AD and those with non-AD medical history) based on case-entering provider's documentation. Data were analyzed with the independent t test for continuous variables, the χ 2 test for binary variables; odds ratios (ORs) and 95% CIs and P values were confirmed through univariate logistic regression using SPSS statistical software (version 22.0; SPSS Inc).
Results
Overall, of 1142 pediatric patch test cases registered between January 1 and December 31, 2015, by 84 unique providers, 552 patients (49%) had a history of AD (data on concurrent AD were available for 98% of the entries). 7 In 338 patients (30%), AD and ACD were concurrent diagnoses reported by the data-entering provider. The mean age of patients with AD was significantly younger than the rest of the study populous-10.5 vs 11.8 years old (P < .001). Almost two-thirds of both AD and non-AD groups were female; sex was not significantly different between patients with AD and the rest of the study population. (Gender identification was missing for 17 patients.) Most patients were
Key Points
Question Does having atopic dermatitis (AD) influence sensitization patterns and allergic contact dermatitis development among children?
Findings In this retrospective case review, which included 1142 children younger than 18 years, those with AD had statistically significant increased frequency of reactions to cocamidopropyl betaine, wool alcohol, lanolin, tixocortol pivalate, and parthenolide, and lower frequency of reaction to methylisothiazolinone, cobalt, and potassium dichromate.
Meaning Children with AD showed significant reaction patterns to allergens found in their skin care preparations.
listed as white non-Hispanic, and this category was significantly more likely to be within the non-AD study population (P < .001). However, those patch-tested patients designated as Asian (OR, 1.92; 95% CI, 1.2-3.1; P = .008) or African American (OR, 4.09; 95% CI, 2.7-6.2; P < .001) were significantly more likely to have AD ( Table 1) . Location of dermatitis prompting patch testing was significantly differed among patients with AD compared with those without. Patients with AD had 4.68 times the odds of having a generalized dermatitis (OR, 4.68; 95% CI, 3.5-6.3; P < .001) and 1.3 times the odds of having dermatitis on the upper extremities (OR, 1.3; 95% CI, 1.0-1.7; P = .03) compared with patients without AD. Patients with AD had significantly longer history of dermatitis than those without AD: 3.5 years vs 1.8 years (P < .001). Overall, 42.2% of patch-tested children with AD had at least 1 RPPT, and 61.1% had at least 1 PPT (Table 1) .
Furthermore, the top 21 prevalent allergens with PPT were assessed among patients with AD, in comparison with the rest of the study sample ( Table 2) . Specifically, in comparison with the patients without AD, those with AD had 7.4 times the odds of having an RPPT to cocamidopropyl betaine (CAPB) (P = .008), 4.2 times the odds of having an RPPT to wool alcohol (P = .047), 4 times the odds of having an RPPT to lanolin (P = .053), 5.3 times the odds of having an RPPT to tixocortol pivalate (P = .02), and 7.6 times the odds of having an RPPT to parthenolide (P = .006). For MI, cobalt, and potassium dichromate, patients with AD had statistically significantly lower odds of having an RPPT compared with the non-AD study population. No statistically significant difference was seen in RPPT rates to nickel among patients with AD compared with the rest of the study sample (OR, 2.39; P = .13) ( Table 2) .
Discussion

Demographics
Patients with AD who were referred for patch testing were, on average, more than 1 year younger than their counterparts without AD and had lived with some form of dermatitis for more than twice as long (3.5 years vs 1.6 years, respectively). Although sex was not significantly different between AD and non-AD groups, girls were patch-tested more often than boys at a 2:1 ratio, consistent with referral patterns noted in prior studies. 6, 8, 9 It remains to be determined as to why girls are referred more frequently for patch testing; however, this may indicate that female children have a higher incidence of contact allergy. If so, increased topical product exposure may be a relevant sensitization route in girls. White children who underwent patch testing were found to be the least likely to have concomitant AD, whereas patchtested Asians and African Americans had significantly higher odds of having AD. The predilection for those with various ancestries and ethnic backgrounds who are referred for patch testing to have a greater likelihood to have ACD and concomitant AD has not been fully elucidated in the literature, and, to our knowledge, we are the first to report such an association. Prior large-scale assessments of patch-tested patients by the NACDG may have had a type II error in assessing the component of race in the association of AD and ACD because it was noted that blacks were underrepresented in NACDG studies. 10, 11 Possible theories for our findings among African American and Asian patients with AD include a possibility that they are more likely to be referred for patch testing because of increased rates of treatment-resistant AD as associated with filaggrin mutations, 12 underlying genetic predilection for AD, 12 reduced minority access to epicutaneous allergy testing, or more frequent misdiagnosis of AD in these racial groups. Conversely, Asian and African American patients without AD may have been less likely to be referred for patch testing for various reasons and, thus, were not captured by our data registry. Future larger studies are necessary to further elucidate the aforementioned associations between AD and ACD across diverse populations.
Dermatitis Type
Patients with generalized dermatitis were significantly more likely to be patch-tested than those with other distributions. This finding is consistent with those of other studies, such as the study by Isaksson et al, 1 which found that scattered generalized dermatitis was the most common distribution in patch-tested children. Patch-tested patients with AD were less likely to have a PPT and RPPT than those in the non-AD group. According to one pathophysiologic theory, this finding may be due to an underlying misbalanced T H 1/T H 2 ratio in severe atopy. [13] [14] [15] [16] It has been noted that patients with severe AD have a conspicuously lower rate of ACD compared with the general population, and compared with those with mild to moderate AD. [17] [18] [19] T H 1 response is limited in severe atopy, with an underlying increase in T H 2; however, T H 1 is critical in development of ACD; thus, these patients with severe AD are in a sense protected from highly sensitizing agents. 16, 19 With our current data set, it is not possible to separate severe AD from mild to moderate AD; therefore, further research is necessary to elucidate this point.
Allergens
Certain trends in sensitization have been noted in our study. Many of the most common allergens, such as fragrance mix, balsam of Peru, bacitracin, formaldehyde, or propylene glycol, were found in similar ratios across both groups (patients with AD and non-AD). Nickel, for example, is the most common positive allergen, but there was no significant difference in rates of PPT from patients with AD compared with those without AD, consistent with results of previous studies. 4 Specifically, sensitization to 5 allergens was noted more frequently in patients with AD than those without AD to a statistically significant degree: CAPB, wool alcohol, lanolin, tixocortol pivalate, and parthenolide (a component of Compositae). These sensitizers are frequently associated with topical medicaments and skin care products. Patients with AD face inherent amplified risk of sensitization because they are primarily treated with topical regimens leading to increased exposure to product-based chemicals, they pathophysiologically have an impaired epidermal barrier, and these chemicals have been reported to have potentially enhancing absorption through the skin. 15, [20] [21] [22] [23] Cocamidopropyl betaine is a surfactant composed of a coconut oil derivative combined with dimethylaminopropylamine and monochloroacetic acid. It is frequently found in shampoos, cleansers, contact lens solutions, and antiseptics. 24 In 2004, it was named "Allergen of the Year" by the American Contact Dermatitis Society (ACDS) and has been noted as an emerging allergen in pediatrics, especially in younger age groups. 4, 25 Our findings correlated with those of other studies, such as Shaughnessy et al, 20 who noted that atopic patients were more likely to be allergic to CAPB, and Zug et al, 6 who found that there was an increased prevalence of PPT to amidoamine, a precursor to CAPB. The frequency of sensitization in patients with mild to moderate AD may be related to increased absorption, due to both the penetrating nature of CAPB and the inherent susceptibility for absorption in AD skin.
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Parthenolide is a sesquiterpene lactone found in Compositae plants, such as ragweed, feverfew, dandelions, sunflowers, and daisies. 24 Exposure to parthenolide may occur in nature, and is associated with summer-exacerbated dermatitis and airbornepattern dermatitis, or as a component of topical preparations such as moisturizers and cleansers. 24,26 While our study showed that patients with AD had significantly higher rates of allergy to parthenolide, the same was not true for Compositae, suggesting that other elements of Compositae may more frequently be responsible for sensitization in patients without AD.
Lanolin is a compound of esters, polyesters, alcohols, and acids extracted from natural wool by using solvents or detergents. 4, 27 It is a popular component of many skin preparations, especially commonly used products in AD, because of its properties as an emollient, moisturizer, emulsifier, adhesive, and plasticizer. 24 Because lanolin is a natural compound, it varies in composition based on its source and processing methods, explaining why some patients may tolerate certain lanolin preparations but not others. 6, 24, 28 Wool alcohols may be removed from lanolin, and this refined lanolin has been noted to elicit fewer responses than lanolin with retained wool alcohol.
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Tixocortol is a class A corticosteroid found in nasal sprays, inhalers, topical hemorrhoid preparations, and buccal and throat medications. Its use in nasal sprays is noteworthy because many patients with AD may also be using these to treat another significant atopic syndrome, allergic rhinitis. Although tixocortol is not typically an ingredient in topical medicaments, 24 other class A corticosteroids, including hydrocortisone, are frequently available over the counter. Sensitization to 3 specific allergens was found to be statistically more common in patients without AD. These were methylisothiazolinone (MI), cobalt, and potassium dichromate. MI is a preservative that is commonly used as a cosmetic preservative for its activity against bacteria and fungi. MI has been well established as a potent allergen, similar to poison ivy. Following with the theory of T H 1/T H 2 imbalance, 3 patients with AD would be less likely to be sensitized to strong sensitizers than their counterparts without AD, 29 which is consistent with our findings on MI.
Cobalt is a metal that is commonly combined with other metals, such as nickel. 24 These cobalt alloys are then used in commonplace items (eg, jewelry, dental and orthopedic implants, and belt buckles). 24 Cobalt may also be used as pigment for porcelain and glass, watercolor paints, crayons, tattoos, and hair dye. Historically, cobalt allergy was seen to be inexorably linked to concomitant exposure to nickel. However, it is increasingly recognized as an independent sensitizer. 30 Two studies 31, 32 from the 1980s and 1990s noted cobalt PPT independent of nickel PPT at rates ranging from 21% to 32%, and the most recent NACDG data showed 40% of patients with PPT to cobalt did not have PPT to nickel. 30 Cobalt was named "Allergen of the Year" in 2016 by the ACDS. 30 Potassium dichromate, an inorganic salt, used in manufacturing and construction. Historically, those at risk for ACD to chromium were textile workers, leather tanners, smelters, and construction workers who work with cement. 24 Similar to cobalt, it is used as a pigment in yellow and green tattoo inks, green felt fabric, cosmetics, radiator coolants, and dental and orthopedic implants. 24 Presumably, in children, sensitization to potassium dichromate is more likely due to pigments rather than occupational metal work. Our findings that potassium dichromate was skewed toward patients without AD are not fully in concordance with other studies. For example, Belloni-Fortina et al 4 found that Italian children with AD had greater prevalence in PPT to potassium dichromate. Future larger studies are necessary to further elucidate the relationship of potassium dichromate sensitivity in patients with AD with specific focus on relevant sources of exposure in children worldwide. Overall, our study provides vital information on the relationship between AD and ACD in pediatric patch-tested patients in the United States. This data set demonstrated that of children evaluated with patch testing, those who had an underlying history of AD tended to be significantly younger, a higher percentage were of Asian or African American descent, and they were more likely to have a generalized-distribution and/or forearm disease and prolonged duration dermatitis compared with those without AD. The allergens found to have significantly higher rates of PPT and RPPT in patients with AD compared with those without AD were ones commonly found in over-the-counter skin care products associated with either treatment of AD or gentle skin care, including CAPB, wool alcohol, lanolin, tixocortol pivalate, and parthenolide. Patients with AD had notably lower rates of PPT or RPPT to MI.
Limitations
Our study had several limitations. Our results may have been affected by misclassification bias because our data were gathered from a variety of providers, which could lead to possible variability in classifying patients as having AD, a relevant positive response, or a particular distribution of dermatitis. The variability in protocol and antigen panels from patch tests performed by the enrolled providers heightens this potential bias. In addition, because the rates of positive and relevant positive results depend on the relative frequency of allergens tested, the overall results may have been affected by differences in the types of patch tests used by individual providers, possibly leading to certain allergens being overrepresented or underrepresented. Because the primary study investigators did not have access to patient medical records, no confirmation of AD status or any additional medical history was available as a quality-control measure. Finally, our results may also be privy to selection bias for the providers who registered into the study, those who entered cases into the registry, and ultimately, the patients evaluated by these providers-because they may not be representative of the general population.
Conclusions
Future larger studies are necessary to further elucidate the results presented in this discussion. To date, the PCDR continues to provide the largest comprehensive collection of US-only pediatric
